balsalazide disodium · Valeant Pharms Intl · NDA 020610
Colazal
Earliest generic entry, as listed
24 Feb 2027
Blocked by patent: US 7452872 (pediatric extension), US 7625884 (pediatric extension).
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7452872 | pediatric extension · sets the listed date | 24 Feb 2027 |
| US 7625884 | pediatric extension · sets the listed date | 24 Feb 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Enters 12-month window basis: patent · 020610-001Listed date 24 Feb 2027Detected 24 Oct 2026
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 020610 · 001 · RLD | capsule, oral | 750MG | 24 Feb 2027 |
Expired or delisted (2)
- US 7452872 · use U-141 · 24 Aug 2026
- US 7625884 · use U-141 · 24 Aug 2026